Surgery for MutYH-associated polyposis (systematic review, meta-analysis)

BACKGROUND: to date, there are no clear guidelines for MutYH-associated polyposis (MAP) surgery.

AIM: to study the world literature on MutYH-associated polyposis surgery using a meta-analysis.

MATERIALS AND METHODS: the systematic review was carried out in accordance with the practice and guidelines of PRISMA. The meta-analysis included the results of 14 case studies, 4 cohort studies, as well as own data on patients with MAP. A total of 474 patients with MAP were analyzed.

RESULTS: when analyzing the number of colorectal polyps, the total occurrence value (95% CI: 0-14) of less than 10 polyps was 10%, in 52% cases (95% CI: 0-100) from 10 to 100 polyps were detected, in the remaining cases there were more than 100 polyps. Colorectal cancer was diagnosed in 56% of patients (95% CI: 45–66) of patients, while tumors with the T1-T3 were found in 38% of cases, tumors with the T4 were found in 7% of cases, lesions of the regional lymph nodes N + were found in 8%. The synchronous tumors were detected in 12%, and metachronous — in 5%. In 87%, some parts of the large intestine were preserved, in 38% [95% CI: 0-100] — colectomy with ileorectal anastomosis, in 27% [95% CI: 23-31] — colorectal resection, in 22% [95% CI: 16-27] — polypectomy), in other cases total removal of all parts of the large bowel was performed.

CONCLUSION: patients with MAP who have been diagnosed with less than 100 colorectal polyps may undergo endoscopic polypectomy, if technically possible. Despite the risk of developing CRC, which in most cases has a nonaggressive course, the clinical course of MutYH-associated polyposis is relatively favorable. For this category of patients, it is possible to limit colorectal resection with annual endoscopic control and removal of detectable polyps in the remaining parts of the large bowel

1. Goodenberger M, Lindor N. Lynch syndrome and MYH-associated polyposis: review and testing strategy. Journal of Clinical Gastroenterology. 2011;45:488–500. DOI:10.1097/MCG.0b013e318206489c

2. Guarinos C, JuarezM, Egoavil C, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clinical. Cancer Research. 2014; 20:1158–1168. DOI:10.1158/1078-0432.CCR-13-1490

3. Syngal S, Brand R, Church J, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. The American Journal of Gastroenterology. 2015;110:223–262. DOI:10.1038/ajg.2014.435

4. Toboeva M.H., Shelygin Yu.A., Frolov S.A., et al. MutYH-associated colonpolyposis. Therapeutic Archive. 2019; 5: 97-100. (in Russ.). DOI:10.26442/00403660.2019.02.000124

5. Tsukanov A.S., Shubin V.P., Kuzminov A.M., et al. Differential diagnosis of MutYH-associated polyposis and sporadic colon polyps. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; 28:51-57. (in Russ.). DOI:10.22416/1382-4376-2018-28-6-51-57

6. Cleary S, Cotterchio M, Jenkins M, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology.2009;136:1251–1260. DOI:10.1053/j.gastro.2008.12.050

7. Jenkins M, Makalic E, Dowty J, et al. Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer screening. Future Oncol. 2016;12:503–513. DOI:10.2217/fon.15.303

8. Tassan N, Chmiel N, Maynard J, et al. Inherited variants of MYH associated with somatic G: C/T:A mutations in colorectal tumors. Nature Genetics. 2002;30:227–232.DOI:10.1038/ng828

9. Win A, Jenkins M, Dowty J, et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:404–412. DOI:10.1158/1055-9965.EPI-16-0693

10. Nielsen M, Adam M, Ardinger H, et al. editors. MutYH Polyposis. 2012 Oct 4 [updated 2019 Oct 10]. Gene Reviews® . Seattle (WA): University of Washington, Seattle; 1993–2021.

11. Landon M, CeulemansS, SaraiyaD.et al.Analysis of current testing practices for biallelic MutYH mutations in MutYH-associated polyposis. Clin Genet. 2015;87:368–372. DOI:10.1111/cge.12375

12. Lu A.-L., Fawcett W. Characterization of the recombinant MutY homolog, an adenine DNA glycosylase, from the yeast Schizosaccharomycespombe. J Biol Chem. 1998;273:25098–25105. DOI:10.1074/jbc.273.39.25098

13. Nielson M, Morreau H, Vasen H, et al. MutYH-associated polyposis (MAP). Critical reviews in Oncology/Hematology. 2011;79:1–16. DOI:10.1016/j.critrevonc.2010.05.011

14. Pearlman R, Frankel W, Swanson B, et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017;3:464–471. DOI:10.1001/jamaoncol.2016.5194

15. Sieber O, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germline mutations in MYH. The New England Journal of Medicine. 2003;348(9):791–799. DOI:10.1056/NEJMoa025283

16. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MutYH-associated polyposis. Gastroenterology. 2009;137:1976–1985. DOI:10.1053/j.gastro.2009.08.052

17. Toboeva M.H. Diagnosis and treatment of MutYH-associated polyposis: dissertation of the Candidate of Medical Sciences. Moscow, 2021 (in Russ.).

18. Nascimbeni R, Pucciarelli S, Lorenzo D, et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. Dis Colon Rectum. 2010;53(12):1670–1675.DOI:10.1007/DCR.0b013e3181ee3d6b

19. Morak M, Laner A, Bacher U, et al. MutYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MutYH mutations and report on novel mutations. Clin Genet. 2010;78(4):353–363.DOI:10.1111/j.1399-0004.2010.01478.x

20. Patel R, McGinty P, Cuthill V, et al. MutYH-associated polyposis – colorectal phenotype and management. Colorectal Dis. 2020;22(10):1271–1278.DOI:10.1111/codi.15078

21. Nieuwenhuis M, Vogt S, Jones N, et al. Evidence for accelerated colorectal adenoma-carcinoma progression in MUTYH-associated polyposis? Gut. 2012;61(5):734-738.DOI:10.1136/gut.2010.229104

22. Casper M, Plotz G, Juengling B, et al. Adenoma development in a patient with MutYH-associated polyposis (MAP): new insights into the natural course of polyp development. Dig Dis Sci. 2010;55(6):1711–1715.DOI:10.1007/s10620-009-0916-z

23. Nielsen M, Poley J, Verhoef S, et al. Duodenal carcinoma in MutYH-associated polyposis. J Clin Pathol. 2006;59(11):1212-1215. DOI:10.1136/jcp.2005.031757

24. De Schepper H, Fierens H, Steger P, et al. MutYH-associated polyposis coli: one common and one rare mutation. Dig Dis Sci. 2012;57(7):1968–70. DOI:10.1007/s10620-012-2107-6.

25. Kidambi T, Goldberg D, Nussbaum R, et al. Novel variant of unknown significance in MutYH in a patient with MUTYH-associated polyposis: a case to reclassify. Clin J Gastroenterol. 2018;11(6):457–460.DOI:10.1007/s12328-018-0870-4

26. Pervaiz M, Eppolito A, Schmidt K. Papillary thyroid cancer in a patient with MutYH-associated polyposis (MAP). Fam Cancer. 2010;9(4):595–597.DOI:10.1007/s10689-010-9366-1

27. Buisine M, Cattan S, Wacrenier A, et al. Identification of a patient with atypical MutYH-associated polyposis through detection of the KRAS c.34G>T mutation in liver metastasis. J Clin Oncol. 2013;31(9):125–127. DOI:10.1200/JCO.2012.44.7391

28. Casper M, Spier I, Holz R, et al. Phenotypic Variability of MutYH-Associated Polyposis in Monozygotic Twins and Endoscopic Resection of A Giant Polyp in Pregnancy. Am J Gastroenterol. 2018;113(4):625–627.DOI:10.1038/ajg.2018.19

29. De Mesquita G, Carvalho B, de Almeida Medeiros K, et al. Intussusception reveals MutYH-associated polyposis syndrome and colorectal cancer: a case report. BMC Cancer. 2019;19(1):324 DOI:10.1186/s12885-019-5505-8

30. Fostira F, Papademitriou C, Efremidis A, et al. An in-frame exon-skipping MUTYH mutation is associated with early-onset colorectal cancer. Dis Colon Rectum. 2010;53(8):1197–1201.DOI:10.1007/DCR.0b013e3181dcf0c1

31. Kacerovska D, Drlik L, Slezakova L, et al. Cutaneous Sebaceous Lesions in a Patient With MutYH-Associated Polyposis Mimicking Muir-Torre Syndrome. Am J Dermatopathol. 2016;38(12):915–923. DOI:10.1097/DAD.0000000000000649

32. Reggoug S, Ropert A, Blayau M, et al. Idiopathic gastric acid hypersecretion in a patient with MutYH-associated polyposis. Am J Gastroenterol. 2009;104(10):2648–2649. DOI:10.1038/ajg.2009.344

33. Tricarico R, Bet P, Ciambotti B, et al. Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MutYH biallelic mutations. Cancer Lett. 2009;274(2):266-70. DOI:10.1016/j.canlet.2008.09.022

34. Weidner T, Kidwell J, Glasgow A, et al. Small Intestine Neuroendocrine Tumor in a Patient With MutYH Adenomatous Polyposis-Case Report and SEER Analysis. Clin Colorectal Cancer. 2018;17(3):545-548. DOI:10.1016/j.clcc.2018.05.002

35. Volkov N, Yanus G, Ivantsov A, et al. Efficacy of immune checkpoint blockade in MutYH-associated hereditary colorectal cancer. Invest New Drugs. 2020;38(3):894-898. DOI:10.1007/s10637-019-00842-z

36. Tsukanov A.S. Strategy of complex molecular genetic study of hereditary forms of colorectal cancer in Russian patients: abstract of the dissertation of the Doctor of Medical Sciences. Moscow, 2017, p. 48. (in Russ.).

37. Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., et al. Practical recommendations for the drug treatment of colon cancer and rectosigmoid compound. Malignanttumors. Practical recommendations of RUSSCO. 2019; 9: 324-364. (in Russ.).

38. Herzig D, Hardiman K, Weiser M, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes. Dis Colon Rectum. 2017;60(9):881–894. DOI: 10.1097/DCR.0000000000000912

39.